E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild to Moderate Bullous Pemphigoid |
|
E.1.1.1 | Medical condition in easily understood language |
Mild to Moderate Bullous Pemphigoid |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10006567 |
E.1.2 | Term | Bullous pemphigoid |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the proportion of subjects who achieve disease control (defined as ≤ 3 new blisters/day and healing of existing blisters) following topical steroid treatment with adjunctive AKST4290 without receiving rescue therapy. |
|
E.2.2 | Secondary objectives of the trial |
To assess treatment safety of the proposed dosing regimen. Additional secondary endpoints include assessment of time to disease control; time to rescue therapy; change in BP Disease Area Index (BPDAI) score by treatment week and at disease control; and change in pruritis as assessed by the BPDAI-Visual Analog Scale (BPDAI-VAS) by treatment week and at disease control. In addition, change in skin (biopsy) eosinophil counts and overall steroid use required to achieve disease control will be assessed. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age 60-95 years, inclusive at screening. 2. Clinical diagnosis of mild or moderate BP at screening: o Mild BP is defined as BPDAI ≤ 10 OR < 10% affected body surface o Moderate BP is defined as BPDAI ≥ 10 and ≤ 55 OR 10-30% affected body surface 3. Treatment naïve or initiation of whole-body high potency topical steroid treatment < 7 days of screening (lesion-only treatment for any amount of time with any topical steroids prior to screening is allowed without restriction). 4. Female subjects must not be pregnant or breastfeeding. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening. WOCBP and men must agree to use highly effective contraception (Clinical Trial Facilitation Group 2014) prior to study entry. A woman is considered of childbearing potential following menarche and until becoming postmenopausal (no menses for at least 1 year without an alternative cause). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in the study, she should inform her treating physician immediately. Male subjects must be willing to use a barrier method contraception while participating in the study. 5. The subject must be able to follow the study procedures and receive the treatment in the established timeframe. 6. The subject must be able to understand the procedures and agree to complete the required assessments. 7. Provide a signed and dated informed consent form in accordance with local regulations and/or IRB/IEC guidelines. |
|
E.4 | Principal exclusion criteria |
1. Severe BP (BPDAI score ≥ 56 OR > 30 new blisters per day OR > 30% affected body surface). 2. Initiation of gliptins and other treatments (e.g., etanercept, sulfasalazine, furosemide, penicillin) that can trigger BP if this treatment was started within 4 weeks prior to screening and is considered possibly related to the onset of BP. 3. Initiation of any concomitant medication in the last 3 months prior to screening and assessed by the investigator as possibly related to the development of BP. 4. Planned use of intravenous immunoglobulin or other concomitant treatments for BP (i.e., doxycycline, dapsone) during the study period. 5. Life expectancy of < 6 months (as assessed by the investigator). 6. Use of systemic immunosuppressants (i.e., mycophenolate, azathioprine, methotrexate) within 4 weeks prior to screening. 7. Treatment with rituximab within 1 year prior to screening. 8. Medical history of: • Myocardial infarction or stroke within 6 months of screening • Active bleeding disorder • Major surgery within 1 month of screening or planned within the study period • Active liver disease • Positive screening test result for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or tuberculosis (TB)(by QuantiFERON testing) 9. Prior treatment within 2 weeks or planned use of strong/potent cytochrome (CYP) P450 3A4/5 (CYP3A4/5) or P-glycoprotein (P-gp) inhibitors or inducers during the study (see Section 17.6.1). 10. Current or planned concomitant use of drugs that are P-gp sensitive substrates and that have a narrow therapeutic index (NTI) (e.g., some factor Xa inhibitors) (see Section 17.6.1). 11. Subjects taking warfarin (see Section 17.6.1). 12. Renal function as defined by estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) study equation (see Section 17.5). 13. Use of systemic steroids (>10 mg prednisone or equivalent/day) within 14 days of first dose of study agent or known diseases (other than BP) that could require the use of systemic steroids within the study period. Subjects who have received a single high-dose of steroids (intravenous or oral) 14 days or more before the administration of the first dose of study drug are eligible for enrollment. 14. Clinically relevant abnormal laboratory value at screening, including hematology, blood chemistry, or urinalysis (laboratory testing may be repeated once during the screening phase). 15. Significant alcohol or drug abuse within past 2 years. 16. Based on ECG reading, subjects with a risk of QT prolongation including: • A baseline prolongation of QTc (using Fridericia’s formula: ≥ 450 ms in men and ≥ 470 ms in women) with confirmation on a repeat ECG. • A history of additional risk factors for Torsades de pointes arrhythmia (e.g., heart failure, hypokalemia, family history of Long QT Syndrome, etc.). 17. The use of concomitant medications known to prolong the QT/QTc interval. 18. Significant medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator, result in the any of the following: • Put the subject at risk because of participation in the study. • Influence the results of the study. • Cause concern regarding the subject’s ability to participate in the study. 19. Malignancy for which the subject is currently undergoing resection, radiation, or chemotherapy. 20. Participation in studies of investigational drugs must have been discontinued within 30 days or 5 half-lives of the drug (whichever was longer) prior to screening.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of subjects who achieve disease control (≤ 3 new blisters/day and healing of existing blisters) without requiring rescue therapy. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At 1-3 weeks depending on when subjects reach disease control. |
|
E.5.2 | Secondary end point(s) |
• Safety as assessed by the incidence, seriousness, and severity of adverse events (AEs). • Time to disease control by treatment Day/Week. • Time to rescue therapy by treatment Day/Week. • Change from baseline in BPDAI score by treatment Week and at disease control. • Change from baseline in pruritus as evaluated by the BPDAI-VAS by treatment week and at disease control. • Change from baseline in skin biopsy eosinophil levels at disease control. • Evaluation of total cumulative steroid exposure at baseline, by treatment Week and at disease control. • Evaluation of maximum daily steroid dose at baseline, by treatment Week and at disease control. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At 1-3 weeks depending on when subjects reach disease control. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 15 |
E.8.9.1 | In the Member State concerned days | |